SV2011003821A - Compuestos de fenantrenona, composiciones y metodos - Google Patents

Compuestos de fenantrenona, composiciones y metodos

Info

Publication number
SV2011003821A
SV2011003821A SV2011003821A SV2011003821A SV2011003821A SV 2011003821 A SV2011003821 A SV 2011003821A SV 2011003821 A SV2011003821 A SV 2011003821A SV 2011003821 A SV2011003821 A SV 2011003821A SV 2011003821 A SV2011003821 A SV 2011003821A
Authority
SV
El Salvador
Prior art keywords
compounds
fenantrenone
compositions
methods
salts
Prior art date
Application number
SV2011003821A
Other languages
English (en)
Inventor
Paul Vicent Rucker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SV2011003821A publication Critical patent/SV2011003821A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPUESTOS DE FORMULA I: (VER FORMULA); O SUS SALES, QUE SON MODULADORES DEL RECEPTOR GLUCOCORTICOIDE. LOS COMPUESTOS Y SALES DE LA INVENCIÓN SON ÚTILES EN EL TRATAMIENTO DE AFECCIONES MEDIADAS POR LA ACTIVIDAD DEL RECEPTOR GLUCOCORTICOIDE.
SV2011003821A 2008-07-28 2011-01-28 Compuestos de fenantrenona, composiciones y metodos SV2011003821A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8409508P 2008-07-28 2008-07-28

Publications (1)

Publication Number Publication Date
SV2011003821A true SV2011003821A (es) 2011-07-28

Family

ID=41037773

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2011003821A SV2011003821A (es) 2008-07-28 2011-01-28 Compuestos de fenantrenona, composiciones y metodos

Country Status (39)

Country Link
US (2) US8148409B2 (es)
EP (1) EP2307375B1 (es)
JP (1) JP4823397B1 (es)
KR (1) KR101377860B1 (es)
CN (1) CN102112446B (es)
AP (1) AP2744A (es)
AR (1) AR072535A1 (es)
AU (1) AU2009278029B2 (es)
BR (1) BRPI0917212A2 (es)
CA (1) CA2729578C (es)
CL (1) CL2011000141A1 (es)
CO (1) CO6290761A2 (es)
CR (1) CR20110012A (es)
CU (1) CU23983B1 (es)
DK (1) DK2307375T3 (es)
DO (1) DOP2011000029A (es)
EA (1) EA018024B1 (es)
EC (1) ECSP11010795A (es)
ES (1) ES2527137T3 (es)
GE (1) GEP20125640B (es)
GT (1) GT201100026A (es)
HK (1) HK1154245A1 (es)
HR (1) HRP20150021T1 (es)
IL (1) IL210492A (es)
MA (1) MA32512B1 (es)
MX (1) MX2011001053A (es)
NI (1) NI201100028A (es)
NZ (1) NZ590559A (es)
PE (1) PE20110559A1 (es)
PL (1) PL2307375T3 (es)
PT (1) PT2307375E (es)
RS (1) RS53747B1 (es)
SI (1) SI2307375T1 (es)
SV (1) SV2011003821A (es)
TW (1) TWI374878B (es)
UA (1) UA99198C2 (es)
UY (1) UY32011A (es)
WO (1) WO2010013158A1 (es)
ZA (1) ZA201101520B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013010576A (es) * 2011-03-15 2014-03-12 Abbvie Inc Moduladores de receptores de hormonas nucleares.
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
WO2014094357A1 (en) 2012-12-21 2014-06-26 Abbvie Inc. Heterocyclic nuclear hormone receptor modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066522A1 (en) 1999-04-30 2000-11-09 Pfizer Products Inc. Glucocorticoid receptor modulators
US6642377B1 (en) 1999-07-30 2003-11-04 Eisai Co., Ltd. Process for the preparation of basic antibiotic-inorganic acid addition salts and intermediate oxalates
ATE327974T1 (de) * 2000-10-28 2006-06-15 Pfizer Prod Inc Modulatoren des glucocorticoid-rezeptors
EP1201660B1 (en) 2000-10-30 2005-08-31 Pfizer Products Inc. Glucocorticoid receptor modulators
PT1521733E (pt) * 2002-07-08 2014-10-29 Pfizer Prod Inc Moduladores do recetor de glucocorticoides
ATE451381T1 (de) 2005-01-19 2009-12-15 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
GB0613836D0 (en) 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
DK2078026T3 (da) 2006-11-21 2012-04-30 Rigel Pharmaceuticals Inc Prodrug-salte af 2, 4-pyrimidinediamine-forbindelser og anvendelser deraf
MX2009006007A (es) 2006-12-05 2009-07-17 Neurogesx Inc Profarmacos y metodos para hacer y usar los mismos.
MX2009008286A (es) * 2007-02-02 2009-08-12 Pfizer Prod Inc Compuestos triciclicos y su uso como moduladores del receptor de glucocorticosteroides.
CN101616925B (zh) * 2007-02-02 2012-05-23 辉瑞产品公司 三环化合物及其作为糖皮质激素受体调节剂的用途

Also Published As

Publication number Publication date
AP2744A (en) 2013-09-30
CO6290761A2 (es) 2011-06-20
US20100069444A1 (en) 2010-03-18
CA2729578C (en) 2014-05-27
KR101377860B1 (ko) 2014-03-25
NZ590559A (en) 2011-09-30
AU2009278029B2 (en) 2012-05-03
DK2307375T3 (en) 2014-12-08
TWI374878B (en) 2012-10-21
EA018024B1 (ru) 2013-04-30
ZA201101520B (en) 2011-10-26
AU2009278029A1 (en) 2010-02-04
PT2307375E (pt) 2015-01-14
IL210492A0 (en) 2011-03-31
JP4823397B1 (ja) 2011-11-24
PE20110559A1 (es) 2011-08-06
TW201014823A (en) 2010-04-16
US8552035B2 (en) 2013-10-08
US8148409B2 (en) 2012-04-03
RS53747B1 (en) 2015-06-30
CN102112446B (zh) 2012-10-31
EA201100080A1 (ru) 2011-08-30
CU23983B1 (es) 2014-03-26
EP2307375A1 (en) 2011-04-13
HRP20150021T1 (en) 2015-03-27
DOP2011000029A (es) 2014-07-31
UY32011A (es) 2010-02-26
AR072535A1 (es) 2010-09-01
GT201100026A (es) 2013-12-10
IL210492A (en) 2015-04-30
WO2010013158A1 (en) 2010-02-04
SI2307375T1 (sl) 2015-02-27
CU20110020A7 (es) 2011-12-28
CR20110012A (es) 2011-02-10
NI201100028A (es) 2011-08-05
US20120157502A1 (en) 2012-06-21
CA2729578A1 (en) 2010-02-04
CN102112446A (zh) 2011-06-29
HK1154245A1 (en) 2012-04-13
BRPI0917212A2 (pt) 2015-11-10
ECSP11010795A (es) 2011-02-28
ES2527137T3 (es) 2015-01-21
JP2011529103A (ja) 2011-12-01
AP2011005562A0 (en) 2011-02-28
MX2011001053A (es) 2011-04-21
GEP20125640B (en) 2012-09-10
MA32512B1 (fr) 2011-07-03
UA99198C2 (ru) 2012-07-25
EP2307375B1 (en) 2014-11-19
KR20110022091A (ko) 2011-03-04
CL2011000141A1 (es) 2011-06-17
PL2307375T3 (pl) 2015-03-31

Similar Documents

Publication Publication Date Title
SV2009003346A (es) Compuestos triciclicos, composiciones y procedimientos.
ECSP11010885A (es) Heteroarilos sustituidos
GT201300164A (es) Derivados de biciclo (3.2.1.) octilamida y sus usos
EA201590292A1 (ru) Соединения, которые являются sip-модулирующими агентами и/или atx-модулирующими агентами
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CL2008003159A1 (es) Compuestos derivados de diaminas sustituidas, sus sales farmaceuticamente aceptables o sus solvatos; compuestos intermediarios; utiles como agentes antiobesidad, mediados por la inhibicion del receptor npy y5.
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
MA32508B1 (fr) Composes organiques
EA201171063A1 (ru) Фармацевтические составы олмесартана
ECSP13012893A (es) Ureas asimétricas y usos médicos de las mismas
ECSP13012600A (es) CO-cristales y Sales de Inhibidores de CCR3
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
CO6321288A2 (es) Sales de compuestos inhibidores de vih
CO6341625A2 (es) Derivados de indol como agentes anticáncer
EA200970662A1 (ru) Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора
BR112014030474A2 (pt) novos compostos bicíclicos de tiofenilamida
SV2011003821A (es) Compuestos de fenantrenona, composiciones y metodos
UY32654A (es) Compuestos 1-(2-alquil-2,3-dihidro-benzofuran-4-il)-pirrolidin-3-ilaminoacilo
CY1114207T1 (el) Παραγωγα βενζοφουρανυλιου για χρηση ως αναστολεις γλυκοκινασης
CU20080116A7 (es) 3-aminociclopentanocarboxamidas como muduladores de receptores de quimioquinas